Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2026
Reporting Period: Event-driven report regarding regulatory feedback received on September 22, 2026.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the receipt of regulatory feedback from the U.S. Food and Drug Administration (FDA) regarding the Company's product candidate, tovecimig, for the treatment of patients with biliary tract cancer (BTC). This feedback pertains to the COMPANION-002 Randomized Phase 2/3 Study.
Guidance, Outlook, and Risks
- Regulatory Pathway: Management intends to discuss the COMPANION-002 study data with the FDA in advance of a planned Biologics License Application (BLA) submission.
- Future Events: The Company expects to present the complete dataset at a medical conference later in 2026.
- Forward-Looking Statements: The filing includes statements regarding the potential of tovecimig as a second-line treatment option for BTC.
- Risks and Contingencies:
- Uncertainty regarding the ability to raise additional funding required for business and product development.
- Inherent uncertainties associated with operating as a development-stage company.
- Risks related to clinical trial completion, regulatory approval, and commercialization.
- Industry competition and market conditions.
Investor Verification Checklist
- Review the full press release attached as Exhibit 99.1 for specific details on the FDA feedback.
- Verify the Company's current cash runway and capital raising plans in the most recent Form 10-K or 10-Q, as this 8-K does not contain financial data.
- Monitor upcoming medical conference presentations for the complete COMPANION-002 dataset.
- Assess the timeline for the planned BLA submission following the anticipated FDA data discussion.